^
Association details:
| Biomarker: | AREG overexpression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies
Excerpt:
Patients with high AREG had longer OS compared with low AREG (HR: 0.227, 95% CI: 0.095-0.808)....Our study has shown that higher T/NT ratios of ERBB2, MET and VEGFA mRNA were associated with worse OS in mCRC patients treated with anti-EGFR antibodies, with higher EREG and AREG were associated with better prognosis in the same setting.
DOI:
10.1038/bjc.2016.74
